Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Aug 28:8:145.
doi: 10.1186/1746-1596-8-145.

The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer

Qiang Lu  1 , Sha Lu, Lijun Huang, Ting Wang, Yi Wan, Chang Xi Zhou, Cunhai Zhang, Zhipei Zhang, Xiaofei Li
Affiliations
Comparative Study

The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer

Qiang Lu et al. Diagn Pathol. .

Abstract

Objective: This article aims to investigate the expression of vacuolar-H + -ATPase (V-ATPase) in non-small cell lung cancer (NSCLC) and its variations with pathological type and grade. Furthermore, to evaluate the chemotherapy drug sensitivity of different cancer tissues as well as its correlation with V-ATPase expression in NSCLC.

Methods: V-ATPase expression was examined in 92 NSCLC tissue samples using the immunohistochemical Envision method and immunofluorescence assay. The location of V-ATPase expression was observed by confocal laser scanning microscopy and the difference of its expression rate was evaluated. The sensitivity of cancer tissues to chemotherapy drug was examined using MTT assay and its correlation with the V-ATPase expression was tested in NSCLC by Spearman rank correlation analysis.

Results: V-ATPase expression was mainly localized in the cell membrane and cytoplasm. The expression rate of V-ATPase was 71.43% in squamous cell lung cancer, significantly lower than that of the lung adenocarcinoma (83.72%, P = 0.000). In different pathological grades of squamous cell lung cancer, the expression rate of V-ATPase was 58.33% in grade II, significantly lower than that of the grade III (84.00%, P = 0.014). The expression rate of V-ATPase in grade II lung adenocarcinoma was 76.67%, significantly lower than that of the grade ΙΙΙ adenocarcinoma (100.0%, P = 0.012). Correlation analysis showed that the sensitivity of NSCLC tissues to cyclophosphamide, gemcitabine, doxorubicin, paclitaxel and cisplatin was significantly correlated with the V-ATPase expression rate (P < 0.05).

Conclusions: V-ATPase was overexpressed in NSCLC. The expression of V-ATPase was related to the pathological type and grade of cancer and was likely associated with chemotherapy drug resistance in NSCLC.

Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7515811511020000.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Expression of V-ATPase in NSCLC. (A): squamous cell lung cancer; (B): lung adenocarcinoma; (A,B): positive staining of V-ATPase in the plasma membrane and cytoplasm; (C): blank (EnVision; 400×).
Figure 2
Figure 2
Location of V-ATPase in NSCLC. (A): squamous cell lung cancer; (B) and (C): lung adenocarcinoma; positive staining of V-ATPase in the plasma membrane and cytoplasm (1000×).
See this image and copyright information in PMC

References

    1. Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, Ramalingam SS. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012;7:866–872. doi: 10.1097/JTO.0b013e31824c7f4b. - DOI - PMC - PubMed
    1. Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008;59:105–110. doi: 10.1016/j.lungcan.2007.07.024. - DOI - PubMed
    1. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K. et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012;109:E2127–E2133. doi: 10.1073/pnas.1203530109. - DOI - PMC - PubMed
    1. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X. et al. Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Rev Anticancer Ther. 2007;7:1405–1421. doi: 10.1586/14737140.7.10.1405. - DOI - PubMed
    1. Huang Y, Sadee W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett. 2006;239:168–182. doi: 10.1016/j.canlet.2005.07.032. - DOI - PubMed

Publication types

MeSH terms

Substances